GlassScriptPhysician profile
Paul K Wielenga
NPI 1235267584
$2,732.34
in general payments reported to CMS, 2019-2025
17 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $472 · 2023: $617 · 2024: $239 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $505.57 | 2024-2025 | Epclusa, Vemlidy |
| Astrazeneca Pharmaceuticals LP | $353.44 | 2022-2025 | Fasenra |
| Edwards Lifesciences Corporation | $149.62 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $146.19 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $135.42 | 2025 | Injectafer |
| Abbvie INC. | $132.69 | 2025 | |
| Horizon Therapeutics Plc | $124.97 | 2023 | Krystexxa |
| Genentech USA, INC. | $122.90 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $122.45 | 2023 | Relyvrio |
| Neurelis, INC. | $121.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $121.95 | 2023 | Quviviq |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Abbott Laboratories | $120.76 | 2025 | Freestyle Libre 3 |
| Argenx US, INC. | $120.06 | 2024 | Vyvgart Hytrulo |
| Shield Therapeutics INC | $119.01 | 2023 | Accrufer |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $116.36 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $97.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wielenga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.